We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

102 hedge funds and large institutions have $1.12B invested in Lexicon Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 27

10% more capital invested

Capital invested by funds: $1.02B → $1.12B (+$100M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

1% less funds holding

Funds holding: 103 → 102 (-1)

Holders
102
Holders Change
-1
Holders Change %
-0.97%
% of All Funds
3.31%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
8
Increased
37
Reduced
27
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UBS AM
UBS AM
Illinois
+$11.9M
2
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Kentucky
+$4.86M
3
BFA
BlackRock Fund Advisors
California
+$3.45M
4
Norges Bank
Norges Bank
Norway
+$990K
5
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$686K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$4.62M
2
Allianz Asset Management
Allianz Asset Management
Germany
-$3.64M
3
Morgan Stanley
Morgan Stanley
New York
-$2.88M
4
Franklin Resources
Franklin Resources
California
-$1.57M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
$603M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$183M +$154K +9,174 +0.1%
UL
3
Ulys LLC
New York
$70.9M – – –
UBS AM
4
UBS AM
Illinois
$33.4M +$11.9M +708,916 +54%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$32.8M -$1.41M -84,040 -4%
Vanguard Group
6
Vanguard Group
Pennsylvania
$30.3M -$4.62M -275,709 -13%
NMC
7
NEA Management Company
Maryland
$27.8M – – –
BFA
8
BlackRock Fund Advisors
California
$27.5M +$3.45M +205,486 +14%
BIT
9
BlackRock Institutional Trust
California
$18.2M -$769K -45,870 -4%
RA
10
Royce & Associates
New York
$10.4M – – –
Schroder Investment Management Group
11
Schroder Investment Management Group
United Kingdom
$8.82M – – –
State Street
12
State Street
Massachusetts
$8.61M -$607K -36,165 -7%
Northern Trust
13
Northern Trust
Illinois
$7.84M -$481K -28,703 -6%
Norges Bank
14
Norges Bank
Norway
$6.01M +$990K +59,032 +19%
Franklin Resources
15
Franklin Resources
California
$5M -$1.57M -93,386 -24%
TRSOTSOK
16
Teachers Retirement System of the State of Kentucky
Kentucky
$4.83M +$4.86M +289,857 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$3.92M -$1.04M -62,213 -21%
GF
18
Gabelli Funds
New York
$3.55M -$105K -6,282 -3%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$3.36M -$356K -21,221 -10%
TCIM
20
TIAA CREF Investment Management
New York
$2.19M -$32K -1,910 -1%
Deutsche Bank
21
Deutsche Bank
Germany
$2.08M +$209K +12,486 +11%
Charles Schwab
22
Charles Schwab
California
$1.77M -$567K -33,819 -28%
BIM
23
BlackRock Investment Management
Delaware
$1.55M +$90.9K +5,421 +6%
SGAM
24
Smith Group Asset Management
Texas
$1.16M -$120K -7,164 -9%
Invesco
25
Invesco
Georgia
$1.13M – – –
1
2 3 4 5

LXRX Hedge Fund Activity: Q3 2013 in Review

102 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2013, worth a combined $1.12B — up 9.9% from $1.02B a quarter earlier.

Fund positioning in LXRX was balanced in Q3 2013: 8 funds opened new positions, 8 closed out, 37 added to existing stakes and 27 trimmed.

The largest buyer was UBS AM, adding an estimated $11.9M. The largest seller was Vanguard Group, cutting an estimated $4.62M.

  • 102 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2013, down from 103 in Q2 2013.
  • Funds reported $1.12B of Lexicon Pharmaceuticals stock for Q3 2013, up 9.9% quarter-over-quarter.
  • 8 funds opened new Lexicon Pharmaceuticals positions in Q3 2013 and 8 closed out, a net change of 0 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2013 was UBS AM, an estimated $11.9M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2013 was Vanguard Group, an estimated $4.62M sold.

Based on aggregated 13F filings for Q3 2013.